Archives of Orthopaedic and Trauma Surgery

, Volume 139, Issue 4, pp 583–588 | Cite as

Factors predicting the 1-year outcome of collagenase treatment for Dupuytren’s disease

  • Anne-Gita Scheibler
  • Miriam Marks
  • Stefanie Hensler
  • Daniel B. HerrenEmail author
  • Maurizio Calcagni



Several studies have investigated the clinical outcome after collagenase treatment for Dupuytren’s disease in terms of range of motion of the affected finger. However, good objective clinical outcome defined by a small remaining flexion contracture does not necessarily translate into satisfactory patient-subjective hand function. The aim of the present study was to identify predictors of patient-reported as well as objective clinical outcome in patients 1 year after collagenase treatment for Dupuytren’s disease.

Materials and methods

Socio-demographic and disease-related data of 92 Dupuytren patients were collected prior to the intervention. Flexion contracture of the most affected finger was measured at baseline and 1 year after treatment. Patients also completed the brief Michigan Hand Outcomes Questionnaire (brief MHQ) before the intervention and at 1-year follow-up. First, univariate correlations using Pearson’s correlation coefficient of the baseline variables with the two target variables were investigated. All variables with r > 0.35 were selected for a multivariate linear stepwise backwards regression model.


The mean brief MHQ score increased between baseline (72 ± 14) and the 1-year follow-up (85 ± 15) (p ≤ 0.001) and baseline flexion contracture decreased from 76° (± 26) to 33° (± 31) (p ≤ 0.001). Higher hand function at baseline (R2 = 0.31) and less flexion contracture (R2 = 0.46) were identified as positive predictors for the outcome 1 year after collagenase treatment for Dupuytren’s disease. Other variables such as age, gender, manual work and if the MCP or PIP joint was affected did not determine outcome in our patient series.


Collagenase treatment resulted in considerable improvement in flexion contracture as well as patient-reported hand function at the 1-year follow-up. Clinicians can expect better outcome after collagenase infiltration in patients with less flexion contracture and in patients showing good initial self-reported hand function.


Dupuytren’s disease Collagenase Clostridium histolyticum Outcome Predictive factor 



We would like to thank Martina Wehrli for her assistance during data collection and Dr Melissa Wilhelmi for manuscript editing.


This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

M. Calcagni has received sponsoring from SOBI for an event on Dupuytren treatment. All other authors have no conflict of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Patient informed consent was obtained from all individual participants included in the study.


  1. 1.
    Wolfe S, Pederson W, Kozin S, Cohen M (2011) Green’s operative hand surgery, 6th edn. Elsevier, AmsterdamGoogle Scholar
  2. 2.
    Gilpin D, Coleman S, Hall S et al (2010) Injectable Collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am 35:2027–2038.e1CrossRefGoogle Scholar
  3. 3.
    Bear BJ, Peimer CA, Kaplan FTD et al (2017) Treatment of recurrent dupuytren contracture in joints previously effectively treated with collagenase Clostridium histolyticum. J Hand Surg Am 42:391:e1–391.e8CrossRefGoogle Scholar
  4. 4.
    Peimer CA, Blazar P, Coleman S et al (2013) Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS Study): 3-year data. J Hand Surg Am 38:12–22CrossRefGoogle Scholar
  5. 5.
    Raven RB, Kushner H, Nguyen D et al (2014) Analysis of efficacy and safety of treatment with collagenase Clostridium histolyticum among subgroups of patients with Dupuytren contracture. Ann Plast Surg 73:286–290CrossRefGoogle Scholar
  6. 6.
    Warwick D, Arner M, Pajardi G et al (2015) Collagenase Clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur 40:124–132CrossRefGoogle Scholar
  7. 7.
    Witthaut J, Jones G, Skrepnik N et al (2013) Efficacy and safety of collagenase Clostridium histolyticum injection for dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg Am 38:2–11CrossRefGoogle Scholar
  8. 8.
    Lipman MD, Carstensen SE, Deal DN (2017) Trends in the treatment of Dupuytren disease in the United States between 2007 and 2014. Hand 12:13–20. CrossRefGoogle Scholar
  9. 9.
    Keller M, Arora R, Schmiedle G, Kastenberger T (2017) Treatment of Dupuytren’s disease with collagenase Clostridium histolyticum. Orthopade 46:321–327. CrossRefGoogle Scholar
  10. 10.
    Van Beeck A, Van den Broek M, Michielsen M et al (2017) Efficacy and safety of collagenase treatment for Dupuytren’s disease: 2-year follow-up results. Hand Surg Rehabil 36:346–349CrossRefGoogle Scholar
  11. 11.
    McMillan C, Yeung C, Binhammer P (2017) Variation in treatment recommendations for Dupuytren disease. J Hand Surg Am 42:963–970.e6. CrossRefGoogle Scholar
  12. 12.
    Degreef I, Vererfve PB, De Smet L (2009) Effect of severity of Dupuytren contracture on disability. Scand J Plast Reconstr Surg Hand Surg 43:41–42. CrossRefGoogle Scholar
  13. 13.
    Zyluk A, Jagielski W (2007) The effect of the severity of the Dupuytren’s contracture on the function of the hand before and after surgery. J Hand Surg Eur 30:326–329CrossRefGoogle Scholar
  14. 14.
    Tsai T, Orav J, Jha A (2015) Patient satisfaction and quality of surgical care in US hospitals. Ann Surg 261:2–8CrossRefGoogle Scholar
  15. 15.
    Engstrand C, Krevers B, Kvist J (2015) Factors affecting functional recovery after surgery and hand therapy in patients with Dupuytren’s disease. J Hand Ther 28:255–260CrossRefGoogle Scholar
  16. 16.
    Zhou C, Hovius SER, Slijper HP et al (2016) Predictors of patient satisfaction with hand function after fasciectomy for Dupuytren’s contracture. Plast Reconstr Surg 138:649–655CrossRefGoogle Scholar
  17. 17.
    Bradley J, Warwick D (2016) Patient satisfaction with collagenase. J Hand Surg Am 41:689–697CrossRefGoogle Scholar
  18. 18.
    Scherman P, Jenmalm P, Dahlin LB (2016) One-year results of needle fasciotomy and collagenase injection in treatment of Dupuytren’s contracture: a two-centre prospective randomized clinical trial. J Hand Surg Eur 41:577–582. CrossRefGoogle Scholar
  19. 19.
    Haase S, Chung K (2018) Bringing it all together. Hand Clin 34:427–436CrossRefGoogle Scholar
  20. 20.
    Ball C, Pratt AL, Nanchahal J (2013) Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice. BMC Musculoskelet Disord 14:131CrossRefGoogle Scholar
  21. 21.
    Knobloch K, Kraemer R, Papst S et al (2012) German version of the brief Michigan hand outcomes questionnaire: implications for early quality of life following collagenase injection in Dupuytren contracture. Plast Reconstr Surg 129:886–887CrossRefGoogle Scholar
  22. 22.
    Waljee J, Kim M, Burns P, Chung K (2011) Development of a brief, 12-item version of the Michigan Hand Questionnaire. Plast Reconstr Surg 128:208–220CrossRefGoogle Scholar
  23. 23.
    McMillan CR, Binhammer PA (2009) Which outcome measure is the best? Evaluating responsiveness of the disabilities of the arm, shoulder, and hand questionnaire, the Michigan hand questionnaire and the patient-specific functional scale following hand and wrist surgery. Hand 4:311–318CrossRefGoogle Scholar
  24. 24.
    Taylor J (1990) Interpretation of the correlation coefficient: a basic review. J Diagn Med Sonogr 6:35–39CrossRefGoogle Scholar
  25. 25.
    Descatha A, Jauffret P, Chastang JF et al (2011) Should we consider Dupuytren’s contracture as work-related? A review and meta-analysis of an old debate. BMC Musculoskelet Disord 12:96CrossRefGoogle Scholar
  26. 26.
    Logan AJ, Mason G, Dias J, Makwana N (2005) Can rock climbing lead to Dupuytren’s disease? Br J Sports Med 39:639–644CrossRefGoogle Scholar
  27. 27.
    Legge, JWHMcFarelane RM (1980) Prediction of results of treatment of Dupuytren’s disease. J Hand Surg Am 5:608–616CrossRefGoogle Scholar
  28. 28.
    Melamed E, Beutel BG, Goldstein S, Angel D (2017) Predictors of outcomes following fasciectomy for Dupuytren’s disease in diabetic and non-diabetic patients. J Hand Surg 22:309–314Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Anne-Gita Scheibler
    • 1
  • Miriam Marks
    • 2
  • Stefanie Hensler
    • 2
  • Daniel B. Herren
    • 1
    Email author
  • Maurizio Calcagni
    • 3
  1. 1.Department of Hand SurgerySchulthess KlinikZurichSwitzerland
  2. 2.Department of Teaching, Research and DevelopmentSchulthess KlinikZurichSwitzerland
  3. 3.Department of Plastic and Hand SurgeryUniversity Hospital ZurichZurichSwitzerland

Personalised recommendations